Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(100.0%)
2Total
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06794281Active Not Recruiting

Synthetic Generation of Hematological Data Over Federated Computing Frameworks: SCD Use Case

Role: collaborator

NCT03800524Phase 3Unknown

Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS

Role: lead

NCT05753852Phase 3Unknown

Open Label Extension of TUDCA-ALS Study

Role: lead

All 3 trials loaded